Literature DB >> 11418715

Diabetic nephropathy and dyslipidaemia.

A Afaq.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11418715      PMCID： PMC1281618          DOI： 10.1177/014107680109400726

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  5 in total

1.  Lovastatin preserves renal function in experimental diabetes.

Authors:  S R Inman; N T Stowe; M D Cressman; B H Brouhard; J V Nally; S Satoh; R Satodate; D G Vidt
Journal:  Am J Med Sci       Date:  1999-04       Impact factor: 2.378

2.  Effect of lipid reduction on the progression of renal disease: a meta-analysis.

Authors:  L F Fried; T J Orchard; B L Kasiske
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

Review 3.  Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.

Authors:  K Jandeleit-Dahm; Z Cao; A J Cox; D J Kelly; R E Gilbert; M E Cooper
Journal:  Kidney Int Suppl       Date:  1999-07       Impact factor: 10.545

Review 4.  Ongoing clinical trials of lipid reduction therapy in patients with renal disease.

Authors:  S Yukawa; M Mune; Y Yamada; H Otani; M Kishino; Y Tone
Journal:  Kidney Int Suppl       Date:  1999-07       Impact factor: 10.545

5.  Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.

Authors:  K S Lam; I K Cheng; E D Janus; R W Pang
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.